Claims
- 1. The method for alleviating inflammation in a living animal body with a minimum of undesirable side effects comprising internally administering to said living animal body an effective amount of a compound selected from the group having the formula: ##STR8## wherein: R is selected from the group consisting of hydrogen and lower alkyl,
- R.sup.1 is selected from the group consisting of hydrogen, lower alkyl, sodium and potassium
- R.sup.2 is selected from the group consisting of hydrogen, halogen having an atomic weight less than 80 and lower alkoxy,
- X is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl,
- Y is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl, and
- Am is selected from the group consisting of primary amino and dimethylamino.
- 2. The method of claim 1 wherein the compound is 2-amino-5-benzoylphenylacetic acid.
- 3. The method of claim 1 wherein the compound is 2-amino-3-benzoyl-5-chlorophenylacetic acid.
- 4. The method of claim 1 wherein the compound is ethyl-2-amino-3-benzoylphenylacetate.
- 5. The method of claim 1 wherein the compound is methyl-2-amino-3-benzoylphenylacetate.
- 6. The method of claim 1 wherein the compound is methyl-2-dimethylamino-3-benzoylphenylacetate.
- 7. The method of claim 1 wherein the compound is 2-dimethylamino-3-benzoylphenylacetic acid.
- 8. The method for alleviating inflammation in a living animal body with a minimum of undesirable side effects comprising internally administering to said living animal body an effective amount of 2-amino-3-benzoylphenylacetic acid.
- 9. The method for alleviating inflammation in a living animal body with a minimum of undesirable side effects comprising internally administering to said living animal body an effective amount of sodium 2-amino-3-benzoyl-5-methoxyphenylacetate sesquihydrate.
- 10. The method for alleviating inflammation in a living animal body with a minimum of undesirable side effects comprising internally administering to said living animal body an effective amount of sodium 2-amino-3-benzoylphenylacetate dihydrate.
- 11. The method for alleviating inflammation in a living animal body with a minimum of undesirable side effects comprising internally administering to said living animal body an effective amount of potassium 2-amino-3-benzoylphenylacetate hydrate.
- 12. A therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of between about 0.1 and 150 milligrams of a compound selected from the group having the formula: ##STR9## wherein: R is selected from the group consisting of hydrogen and lower alkyl,
- R.sup.1 is selected from the group consisting of hydrogen, lower alkyl, sodium and potassium,
- R.sup.2 is selected from the group consisting of hydrogen, halogen having an atomic weight less than 80, and lower alkoxy,
- X is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl,
- Y is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl, and
- Am is selected from the group consisting of primary amino, and dimethylamino, and
- (b) a pharmaceutically acceptable carrier therefor.
- 13. The composition of claim 12 wherein the compound is 2-amino-5-benzoylphenylacetic acid.
- 14. The composition of claim 12 wherein the compound is 2-amino-3-benzoyl-5-chlorophenylacetic acid.
- 15. The composition of claim 12 wherein the compound is ethyl 2-amino-3-benzoylphenylacetate.
- 16. The composition of claim 12 wherein the compound is methyl 2-amino-3-benzoylphenylacetate.
- 17. The composition of claim 12 wherein the compound is methyl 2-dimethylamino-3-benzoylphenylacetate.
- 18. The composition of claim 12 wherein the compound is 2-dimethylamino-3-benzoylphenylacetic acid.
- 19. A therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of between about 0.1 and 150 milligrams of sodium 2-amino-3-benzoylphenylacetic acid and (b) a pharmaceutically acceptable carrier thereof.
- 20. A therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of between about 0.1 and 150 milligrams of sodium 2-amino-3-benzoyl-5-methoxyphenylacetate sesquihydrate and (b) a pharmaceutically acceptable carrier thereof.
- 21. A therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of between about 0.1 and 150 milligrams of sodium 2-amino-3-benzoyl-phenylacetate dihydrate and (b) a pharmaceutically acceptable carrier thereof.
- 22. A therapeutic composition suitable for alleviating inflammation comprising (a) an effective amount of between about 0.1 and 150 milligrams of potassium 2-amino-3-benzoylphenylacetate hydrate and (b) a pharmaceutically acceptable carrier thereof.
- 23. A compound selected from the group having the formula: ##STR10## wherein; R is selected from the group consisting of hydrogen and lower alkyl,
- R.sup.1 is selected from the group consisting of hydrogen, lower alkyl, sodium and potassium,
- R.sup.2 is selected from the group consisting of hydrogen, halogen having an atomic weight less than 80, and lower alkoxy,
- X is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl,
- Y is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl, and
- Am is selected from the group consisting of primary amino (-NH.sub.2) and dimethylamino.
- 24. The compound of claim 23 which is 2-amino-5-benzoylphenylacetic acid.
- 25. The compound of claim 23 which is 2-amino-3-benzoyl-5-chlorophenylacetic acid.
- 26. The compound of claim 23 which is ethyl 2-amino-3-benzoylphenylacetate.
- 27. The compound of claim 23 whcih is methyl 2-amino-3-benzoylphenylacetate.
- 28. The compound of claim 23 which is methyl 2-dimethylamino-3-benzoylphenylacetate.
- 29. The compound of claim 23 which is 2-dimethylamino-3-benzoylphenylacetic acid.
- 30. A compound selected from the group having the formula: ##STR11## wherein; R is selected from the group consisting of hydrogen and lower alkyl,
- R.sup.2 is selected from the group consisting of hydrogen, halogen having an atomic weight less than 80 and lower alkoxy,
- R.sup.3 is selected from the group consisting of calcium and magnesium,
- X is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl,
- Y is selected from the group consisting of hydrogen, lower alkyl, halogen having an atomic weight less than 80, nitro and trifluoromethyl, and
- Am is selected from the group consisting of primary amino (--NH.sub.2) and dimethylamino.
- 31. Calcium 2-amino-3-benzoylphenylacetate dihydrate.
- 32. Magnesium 2-amino-3-benzoylphenylacetate trihydrate.
- 33. 2-Amino-3-benzoylphenylacetic acid.
- 34. Sodium 2-amino-3-benzoyl-5-methoxyphenylacetate.
- 35. Sodium 2-amino-3-benzoyl-5-methoxyphenylacetate sesquihydrate.
- 36. Sodium 2-amino-3-benzoylphenylacetate.
- 37. Sodium 2-amino-3-benzoylphenylacetate dihydrate.
- 38. Potassium 2-amino-3-benzoylphenylacetate.
- 39. Potassium 2-amino-3-benzoylphenylacetate hydrate.
- 40. Sodium 2-amino-3-(p-chlorobenzoyl)phenylacetate hydrate.
- 41. Ethyl 2-amino-3-(p-chlorobenzoyl)phenylacetate.
- 42. Sodium 2-amino-3-benzoyl-.alpha.-methylphenylacetate hydrate 2.5.
- 43. 2-Amino-3-(p-fluorobenzoyl)phenylacetic acid.
- 44. Sodium 2-amino-3-(p-fluorobenzoyl)phenylacetate hydrate.
- 45. Calcium 2-amino-3-benzoylphenylacetate.
- 46. Magnesium 2-amino-3-benzoylphenylacetate.
- 47. 2-Amino-3-(p-methoxybenzoyl)phenylacetic acid.
Parent Case Info
This application is a continuation-in-part application of copending application Ser. No. 487,499 filed July 11, 1974, now abandoned which is a continuation-in-part application of copending application Ser. No. 354,625 filed Apr. 25, 1973, now abandoned, which application is a continuation-in-part application of copending application Ser. No. 254,285 filed May 17, 1972, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3828093 |
Bays et al. |
Aug 1974 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2,324,768 |
Nov 1973 |
DT |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
487499 |
Jul 1974 |
|
Parent |
354625 |
Apr 1973 |
|
Parent |
254285 |
May 1972 |
|